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Abstract
Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that
increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients
remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights
recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical
markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on
bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification
and management of diabetic patients at increased fracture risk.
Keywords Diabetes . Diabetes-related bone disease . Fracture . Osteoporosis
Epidemiology of diabetes and related
fractures
Worldwide, one in 11 adults globally is estimated to have diabe-
tes. The global prevalence of type 1 and type 2 diabetes in adults
is currently estimated to be close to 425 million, with an expect-
ed increase to 629 million by 2045 [1]. In addition, there are an
estimated 318 million adults with impaired glucose tolerance.
A meta-analysis including nearly 140,000 subjects with
fractures reported a pooled relative risk (RR) of any fracture
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of 3.16 (95% CI 1.51–6.63; p = 0.002), hip fractures of 3.78
(95% CI 2.05–6.98; p < 0.001), and spine fractures of 2.88
(95% CI 1.71–4.82; p < 0.001) in type 1 diabetes [2]. The RR
of a hip fracture in women with type 1 diabetes was 5.19 (95%
CI 2.22–12.11, p < 0.001) compared to women without dia-
betes [2]. Weber et al. showed that increased risk of fractures
extended across the life span, with hip fracture incidence oc-
curring 10 to 15 years earlier in patients with type 1 diabetes
than in those without [3].
An increased fracture risk has also been reported in some
studies of type 2 diabetes [4, 5], but not others [6, 7]. In a
middle-aged population of 33,000, diabetes was the strongest
predictor of low-energy fracture in bothmen and women, with
RR of 2.38 and 1.87, respectively [8]. In a meta-analysis of
patients with type 2 diabetes, the summary RR of fractures at
thehip inmenwas2.8 [1.1, 6.6] and inwomen2.1 [1.6. 2.7] [9].
When contrasting the risk of fractures in type 1 diabetes
from type 2 diabetes, Vestergaard reported an odd ratio (OR)
for hip fracture of 1.38 [1.2–1.6] in type 2 diabetes compared
to 1.70 [1.3–2.2] in type 1 diabetes [4], although the latter was
likely to be underestimated. Indeed meta-analyses published
by Janhorbani [9] and Vestergaard [10] showed a stronger
association and effect size for type 1 diabetes (RR 6.3 and
6.94 respectively) compared to type 2 diabetes (RR 1.7 and
1.38 respectively), in both men and women.
With an OR for osteoporotic fracture in patients with type 2
diabetes of about 1.5, only about 4% of the global osteoporotic
fracture burden is statistically attributable to diabetes.
However, considering the increasing prevalence of diabetes
and the fact it may also be associated with greater risk for
(injurious) falls [11], fragility fractures increasingly appear
as a serious, yet neglected complication of this disease.
Nevertheless, the link between diabetes and skeletal health
receives only cursory attention in osteoporosis guidelines
and even less in clinical diabetes guidelines [12].
Diabetes-related risk factors for fractures
Certain individualswith diabetes seem to be at greater risk of
fracture than others. Hence, in type 2 diabetes, age and dura-
tionof diabetes are clearly important [4, 13–15]. In the cohort
fromManitoba, Canada, consisting of men and women aged
40 years and older with or without diabetes (n = 6455/55′
958), diabetes was a significant independent risk factor for
major osteoporotic fractures (MOF) (hazard ratio (HR) 1.32;
95%CI 1.20–1.46). However, age significantlymodified the
effect of diabetes on hip fracture risk, with younger subjects
having a higher relative risk, as the background risk rises in
the overall population with aging (adjusted (a) HR age < 60,
4.67 [95% CI 2.76–7.89], age 60–69, 2.68 [1.77–4.04], age
70–79, 1.57 [1.20–2.04], age > 80, 1.42 [1. 10–1.99]; p in-
teraction < 0.001) [15].
Astudyhas suggested that fracture risk is not increasedwith-
in the first 5 years of diabetes [16], while Ivers et al. observed
highriskofanyfractureonly inpatientswithdiabetes for at least
10 years [17]. A biphasic pattern has been proposed where
fracture risk is in fact decreased in newly diagnosed type 2
diabetes, −which could be related to some protective effects of
increased fatmass in these subjects–, and only increases signif-
icantly after 5 years [18]. In FRAX-adjusted analyses, only
duration longer than 10 years was associatedwith a higher risk
for MOF (HR 1.47, [1.30–1.66]) [19].
A meta-analysis in 2007 [10] did not reveal a clear associ-
ation between fracture risk and glycemic control. However,
recent observational and association studies reported in-
creased fracture risk with worsening control as defined by
glycated hemoglobin A1c (HbA1c) levels ≥ 7% [20, 21]. A
clinical trial of glycemic control reported that maintaining a
median A1c of 6.4% did not reduce fracture risk compared
with a median A1c of 7.5% [22], but this trial could not assess
effects of poor (> 8%) control on fracture risk. Diabetes has
also been shown to be predictive of increased post-fracture
mortality risk among patients with hip fractures [23, 24].
Consistent with the notion that longer duration and/or poor
glycemic control could further increase fracture risk in diabe-
tes, recent studies have shown that bone microstructural alter-
ations are more prominent among diabetics with microvascu-
lar complications (see below) [25].
Impact of diabetesmedication on fracture risk
The relationship between diabetes and bone fragility and
therefore the identification of those individuals at increased
risk of fracture is further complicated by the variable effects
of diabetes medication on the skeleton (Table 1). Although
there is no prospective trial on the effects of diabetes medi-
cation on bone fragility, results from observational and epi-
demiological studies and from adverse events in diabetes
Table 1 Effects of diabetes medications on BMD and the risk of
fracture in type 2 diabetes
Medications BMD Risk of fracture
Metformin [4, 26] =/↑ ↓/=
Sulphonylureas [26] NA ↓/=/↑
Thiazolidinediones [27, 28] ↓↓/= ↑↑/=
Incretins
GLP1 analogue [29]
DPP4 inhibitor [30, 31]
↑/=
--
=
↓/=
SGLT2 inhibitors [32–34] = =/↑
Insulin [35] = ↑
↑ increase, ↓ decrease, = unchanged, NA not available, GLP glucagon-
like peptide, DPP4 dipeptidyl peptidase inhibitor 4, SGLT2 sodium/
glucose cotransporter 2, BMD bone mineral density
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clinical trials have brought important insights into the po-
tentially beneficial or deleterious effects of these medica-
tions on fracture risk.
Conventional medications
Observational studies have often reported an increased frac-
ture risk in patients taking insulin [26]. Patients receiving in-
sulin (and possibly insulin secretagogues) are at higher risk of
fracture, through an indirect effect, in part because of
hypoglycemia-induced falls [36, 37]. It is also possible that
those on insulin suffer from diabetes for a longer duration and/
or have a poorer glycemic control (i.e., over 5 years ago) with
the disease-related complications (retinopathy, neuropathy)
[38, 39] that could further contribute to falls and fracture risk.
In vitro studies have shown a positive effect of metformin
on RUNX2 expression, improving, in turn, bone formation
[38]. Clinical data confirmed either a neutral or a positive
effect on fractures, making this widely used medication a safe
option with regard to bone health [38].
Although in vitro data have not proved a direct effect of
sulphonylureas on bone, epidemiological data have revealed
an increased risk of fractures in treated patients. It has been
hypothesized that the high risk of hypoglycemic events related
to sulphonylureas may increase risk of falls and, by conse-
quence, risk of fractures [38].
A number of both in vitro studies and clinical trials have
proven that both rosiglitazone and pioglitazone treatment
cause bone loss [40]. Thiazolidinediones (TZD) interact with
peroxisome proliferator-activated receptor (PPAR)γ, which
favors adipocyte differentiation at the expense of the osteo-
blast differentiation and regulates gene expression involved in
adipogenesis, glucose homeostasis, and inflammation. A re-
cent meta-analysis has pointed out that pioglitazone may play
a negative role only in females with data not showing a sig-
nificant risk for males. Current guidelines suggest avoiding
pioglitazone in postmenopausal women or in men with other
risk factors for bone fragility.
Newer medications
Both incretin mimetics, dipeptidyl peptidase-4 (DPP4) inhib-
itors and glucagon-like peptide-1 (GLP-1) analogs, have a
safe skeletal profile in type 2 diabetes, likely because the pos-
itive effect of GLP-1 on bone formation and the low risk of
hypoglycemic events [40].
Recent reports from the CANVAS study on sodium-
glucose cotransporter 2 (SGLT2) inhibitors have indicated de-
creased bone density and higher risk of fractures in patients
treated with canagliflozin [32]. The mechanisms for
canaglifozine negative effects on bone are not entirely clear
but SGLT2 inhibitors inhibit the proximal tubular reabsorption
of glucose, while increasing phosphate reabsorption, thereby
increasing serum phosphate levels that can be a trigger for
PTH and increased bone turnover.
In contrast, the limited available data for empagliflozin and
dapagliflozin have not raised concerns for bone fragility [33].
A recent meta-analysis of 20 SGLT2 inhibitor trials actually
has not confirmed an increased risk of fractures with
dapagliflozin, empagliflozin, or canagliflozin [41]. More data
are necessary to understand the effect of these new medica-
tions on bone health. Nevertheless, at the moment,
empagliflozin and dapagliflozin may be preferred in diabetic
patients with known bone fragility.
DXA and bone ultrasound
Most studies have shown that people with type 1 diabetes have
lowerbonemineral density (BMD)comparedwithhealthy sub-
jects [42]. It might be expected that obesity, which is a strong
risk factor for type 2 diabetes, would protect against osteoporo-
sis because of the known positive correlation between body
mass index (BMI) andBMD. Indeed, type 2 diabetes is usually
associated with a 5 to 10% higher areal BMD than healthy
subjects [5,10,13,43], thoughthere issignificantheterogeneity
between studies [43]. The increase in BMD was more pro-
nounced in younger men, in the presence of higher BMI
and—perhaps surprisingly—higher HbA1c levels [43]. The
higher BMD was predominantly a feature of the weight-
bearing skeleton but not of nonweight-bearing sites such as
the forearm [5]. However, the higher BMD noted in type 2
diabetesmayalsobe independentof the increased skeletal load-
ing as higher BMD persists even after adjustment for BMI in
numerous cohort studies [43]. An Asian study also reported
subjects with type 2 diabetes and hip fracture who are under-
weight, with a higher BMD compared to non-diabetic counter-
parts, suggesting other mechanisms for the higher BMD, such
as persistent hyperglycemia related to insulin resistance [44].
This relatively higher BMD in those with type 2 diabetes
implies that an even lower proportion of subjects with fracture
will have a BMD T-score in the osteoporotic range (i.e., T-
score ≤ −2.5) than among the non-diabetic population.
Schwartz et al. showed that for a given T-score and age, the
fracture risk was higher in type 2 diabetes patients compared
to patients without type 2 diabetes [45].Moreover, a T-score in
a woman with diabetes is associated with hip fracture risk
equivalent to a woman without diabetes with a T-score of
approximately 0.5 units lower [45]. Nevertheless, data have
clearly confirmed that while BMD systematically underesti-
mates fracture risk, it still stratifies fracture risk in elderly
patients with diabetes [46].
Some studies suggest that type 2 diabetes may also be asso-
ciated with more rapid bone loss, which could also partially
explain the increased rateoffractures.Schwartzetal. [47] found
that older women with diabetes lose bone more rapidly than
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those without type 2 diabetes at many skeletal sites, but not the
radius. Leslie et al. recently published that in a large registry-
based study forManitoba,womenwithdiabeteshadmarginally
greater BMD loss at the femoral neck but not at other sites
compared to a control population without diabetes [48].
Contrarily to BMD, spine trabecular bone score (TBS)
tends to be lower among diabetes patients than controls [49,
50]. Moreover, within the type 2 diabetes group, TBS was
better in those with good glycemic control compared to those
with poor glycemic control. Hence TBS was found to be a
BMD-independent predictor of fracture and predicted fractures
equally well in those with (aHR 1.27, 95% CI 1.10–1.46) and
without diabetes (HR 1.31, 95% CI 1.24–1.38). To be noted,
however, that the gradient of risk per 1 SD decrease in TBS
remains less than for BMD in diabetic patients, whereas dia-
betes itself remains an independent risk factor for fractures
even after adjustment for BMD and TBS [50]. Recent analyses
indicate that TBS as evaluated on Hologic dual-energy x-ray
absorptiometry (DXA) devices is inversely related to BMI and
abdominal fat [51]. Whether TBS represents alterations of
bone structure in diabetes therefore remains unknown.
There exist conflicting results with studies conducted using
calcaneal ultrasound. In one study using quantitative ultra-
sound, speed of sound (SOS) measurements at the radius were
significantly decreased in type 2 diabetes compared to controls
[52], while another study reported that calcaneal SOS was not
different between type 2 diabetes patients with prevalent verte-
bral fractures (VFs) compared to those without VFs [53].
Microarchitecture and bone quality
Since reduced BMD alone does not fully explain bone fragil-
ity, particularly not in type 2 diabetes, alteration in Bbone
quality^ is being investigated using various techniques. With
magnetic resonance imaging (MRI), Pritchard et al. measured
larger holes in trabecular network of type 2 diabetes compared
to controls at baseline [54]. Using HR-pQCT (Xtreme CT) at
the distal radius and/or tibia, studies in postmenopausal wom-
en with or without diabetes suggest that there is a trend to-
wards greater cortical porosity in type 2 diabetes compared to
controls [55–57]. In 99 elderly women with type 2 diabetes
and 954 age-matched controls from the Gothenburg Study,
Nilsson et al. reported higher cortical porosity at the distal
radius but not at the distal tibia in subjects with type 2 diabetes
(+ 16%, p < 0.001) [58]. However, they did not find any other
alteration in the trabecular or cortical microarchitecture nor
decreased estimated bone strength among diabetics in this
cohort [58]. Trabecular bone volume is more heterogeneous
and is preserved or (apparently) increased [55], though the
latter may arise from the trabecularization of the cortex [59].
Furthermore, the increased cortical porosity and larger trabec-
ular heterogeneity is more evident in type 2 diabetes with
fractures compared to type 2 diabetes without prevalent frac-
tures [56]. In African-American women with diabetes, cortical
porosity was reported to be 26% greater while cortical volu-
metric BMD (vBMD) was lower compared to controls [60]. A
recent study of 52 subjects with type 2 diabetes, of whom 25
had microvascular disease demonstrated, such cortical deficits
noted on HR-pQCT were only present in patients with the
microvascular complications [25]. Higher cortical porosity in
mid-cortical and periosteal layers in type 2 diabetes patients
with prior fracture compared to type 2 diabetes without frac-
tures suggests that these cortical sub-compartments might be
sensitive to type 2 diabetes-induced toxicity and may reflect
microvascular disease [61].
Bone strength estimated by microfinite element analysis
(micro-FEA) was shown to be lower in type 2 diabetes com-
pared to controls in association with increased cortical poros-
ity at the distal radius [55, 58]. Furthermore, in type 2 diabetes
with fractures, stiffness, failure load, and cortical load fraction
were significantly decreased at the ultradistal and distal tibia
compared to type 2 diabetes without fractures and this deficit
is related to the higher cortical porosity [56]. However, it is
unlikely that HR-pQCTwill become sufficiently widely avail-
able for routine clinical purposes. DXA-derived surrogates for
cortical bone volume and strength may provide additional
information regarding cortical alterations in diabetes, as well
as having potentially widespread accessibility.
Finally, few studies using microindentation of the tibia out-
er cortex have suggested that the estimated bone material
strength index (BMSI) is decreased in type 2 diabetes com-
pared to controls [58, 62], which could reflect alterations in
collagen crosslinks by advanced glycation end products
(AGEs) and in mineralization (also see below) [63]. These
findings are consistent with the concept of Bdiabetoporosis^
as previously suggested to characterize the bone fragility in
this particular population [64].
Bone turnover: histomorphometry and serum
markers
The gold standard for the study of bone turnover is quantita-
tive bone histomorphometry. One of the best estimates of bone
turnover rate is the bone formation rate divided by the surface
referent (BFR/BS) and this has been shown to be decreased in
diabetes at the cancellous, endocortical and intracortical sur-
faces by 70–80%. In two small studies, reductions in the min-
eralizing surface and the osteoblast surface (5 patients) and
low bone formation (6 patients) have been reported [65, 66].
Most biochemical studies show that bone formation
markers, procollagen type I N-terminal propeptide (PINP)
and osteocalcin (OC) and the bone resorption markers c-
telopeptide (CTX) and tartrate-resistant acid phosphatase 5b
(TRAcP5b) activity are usually reduced in type 2 diabetes [38,
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67, 68], whereas bone-specific alkaline phosphatase (BSAP)
[69] and N-terminal telopeptide (NTX)/creatinine (Cr) [70,
71] are usually normal or slightly elevated.
It is noteworthy that in the context of a low bone turnover,
the mechanisms for an apparent increase in the cortical poros-
ity remain unexplained.
Other biochemical markers of bone fragility
in diabetes
The bone content of pentosidine, the most abundant AGE [72,
73] in non-diabetics with hip fracture was greater than in those
without hip fracture [74]. Bone pentosidine levels are related
to the strength of the human vertebra, independent of BMD
[73]. Increased levels of serum pentosidine, AGEs, and solu-
ble receptors for advanced glycation end products (sRAGE)
were reported in type 2 diabetes compared with controls [75,
76]. Serum pentosidine was associated with greater risk of
vertebral fracture in patients with type 2 diabetes [77], while
urinary pentosidine is associated with an increased risk of
clinical and vertebral fractures [78, 79]. Serum endogenous
secretory RAGE (esRAGE) was inversely related to the risk
of vertebral fracture in type 2 diabetes and the effect was
independent of BMD [80].
Sclerostin, an inhibitor of the Wnt/β-catenin pathway and
therefore an inhibitor of bone formation, was found to be
significantly increased in type 2 diabetes compared to controls
[81, 82]; and sclerostin levels have been shown to be positive-
ly correlated with fragility fractures in type 2 diabetes [83, 84].
Conversely, sclerostin levels were inversely associated with
fracture risk in type 1 diabetes patients: the patients with the
highest tertile of sclerostin had an 81% decreased risk of a
fracture compared to the lowest tertile [85]. Whether any in-
crease in circulating levels of sclerostin directly reflects an
osteocytic dysfunction and/or is a marker of the vascular dis-
ease in type 2 diabetes patients remains unknown [86].
In this context, another new marker of osteocytic and peri-
osteal cells activity may be of interest. Serum periostin and
particularly its digested fragments have recently been associ-
ated with fracture risk in non-diabetes patients [87] and are
currently under study in large diabetes population. In addition,
serum microRNAs (miRNA) have been found to be altered in
diabetes and that might explain some of the alterations in bone
cell functions related to diabetes [88].
Anti-osteoporosis treatments in diabetic
patients
No randomized clinical trials have directly evaluated the anti-
fracture efficacy of osteoporosis treatment in diabetic patients;
management is therefore largely empirical and derives from
the good clinical practice and experience of the physician.
The clinical evidence regarding the efficacy of anti-
osteoporosis treatments in diabetic patients is therefore pro-
vided by post hoc analyses in subgroups from randomized
clinical trials that primarily enrolled osteoporosis patients
and from a few observational studies (Table 2).
In the Fracture Intervention Trial (FIT), postmenopausal
women including diabetic participants with a femoral neck T-
score < −1.6 were randomly treated with alendronate or placebo
for 3 years. In a post hoc analysis, Keegan et al. [89] reported
that diabetes did not alter the effect of alendronate on BMD gain
vs placebo. Similarly, two relatively small observational studies
showed than alendronate improved lumbar spine BMD but not
hipBMD similarly in postmenopausal osteoporotic patients with
and without diabetes [96, 97]. Data extracted from the Danish
national prescription registry reported that diabetes, with or with-
out complications, did not influence fracture risk in patients who
adhered to alendronate [90]. Another Danish cohort study found
no difference in the anti-fracture efficacy of alendronate or eti-
dronate at the hip, lumbar spine, and forearm [91]. Furthermore,
this study concluded that risk of hip fracture with these treat-
ments was similar in type 1 diabetes, type 2 diabetes, and non-
diabetic patients [91]. In osteoporotic Japanese women with
diabetes in 3 phase III trials, risedronate treatment showed sim-
ilar responses on lumbar spine BMD and bone markers between
diabetic and non-diabetic patients [92]. There are no data regard-
ing IV bisphosphonates (ibandronate, zoledronic acid) in diabet-
ic patients; renal impairment may limit the utility of these ther-
apies in diabetics. Data are not currently available regarding the
anti-fracture efficacy of denosumab or the effects of discontinu-
ation in those with diabetes. Considering that anti-resorptive
treatments decrease bone turnover and increase the degree of
mineralization, their effects on whole bone strength and fracture
risk without low BMD remain to be ascertained.
In theMORE trial, univariate analysis showed a higher effi-
cacy of raloxifene in reducing vertebral fracture risk in diabetic
women compared to those without diabetes (p = 0.04) [93].
Anti-fracture efficacy of raloxifene was similar between pa-
tients with and without diabetes in the RUTH (Raloxifene Use
for The Heart) trial and in a Danish cohort [91, 94].
Table 2 Effects of osteoporosis medications on BMD and the risk of
fracture in type 2 diabetes
Medications BMD Risk of fracture
Alendronate [89–91] ↑ NA/=
Etidronate [91] NA =
Risedronate [92] ↑ NA
Raloxifene [91, 93, 94] NA ↓/=
Denosumab NA NA
Teriparatide [95] ↑ =
↑ increase, ↓ decrease, = unchanged, NA not available, BMD bone min-
eral density
Osteoporos Int (2018) 29:2585–2596 2589
Post hoc analyses of the DANCE study (Direct Analysis of
Non-vertebral Fractures in the Community Experience)
assessed the effects of teriparatide (20 μg/d SQ up to
24 months) on skeletal outcomes in patients with and without
type 2 diabetes. Teriparatide treatment had a similar effect in
diabetic vs non-diabetic persons on vertebral and total hip
BMD. Interestingly, the effect on femoral neck was greater
in the diabetic treated patients compared to those without di-
abetes. Incidence of non-vertebral fracture at 6 months was
similar in both groups [95]. Nevertheless, because complicat-
ed diabetes could be associated with cortical porosity and
teriparatide has been reported to increase cortical porosity
[98], the effects of teriparatide on bone strength and fracture
risk in severe diabetics remain to be specifically evaluated.
New and future osteoporosis medications
Abaloparatide may have potential in the treatment of bone fra-
gility indiabetes as it can stimulate bone formationwith a lesser
increase in bone resorption. Romosozumab, an anti-sclerostin
antibody, is currently under investigation as a new anabolic
treatment [99] and has been shown to enhance bone mass and
strength in diabetic animals [100]. Whether it could improve
bone health in diabetics is of great interest. Recent signals of
increased cardiovascular risk compared to alendronate raise
safety concerns, especially in diabetic populations [101].
The above results obtained from observational studies and
post hoc analyses are promising but ideally, the efficacy of
osteoporotic treatments in diabetic patients should be demon-
strated in prospective RCTs specifically recruiting patients
with diabetes and fragility fractures or high fracture risk.
Management of bone fragility in adults
with diabetes
Criteria to establish a diagnosis of osteoporosis are based on
the presence of fragility fracture and/or a low BMD. These
strict diagnostic criteria have to be differentiated from treat-
ment thresholds. Since prior fracture predicts risk for future
fracture as strongly in diabetic as in non-diabetic patients
[15], treatment should be initiated when a patient with dia-
betes meets the intervention guidelines for the general pop-
ulation (Fig. 1). Otherwise, treatment should be considered
Diabetes
Hip or vertebral fracture
(>1 other fragility fracture1 )
Morphometric 
vertebral 
fracture 
T-Score < -2.0 *
FRAX**
(adjusted for 
diabetes***)
No other CRFs
< country-speciﬁc
intervenon threshold
Osteoporosis Therapy
Repeat DXA/FRAX 
every 2-3 years
Yearly clinical 
reassessment for advent 
of relevant fractures and  
risk factors and every 2 
years for BMD 
> country-speciﬁc
intervenon threshold
Other fracture1 No fracture
DXA (incl. VFA & TBS
if possible)
diabetes-
speciﬁc CRF+
and/or age > 
50 years
and/or 
Fig. 1 Fracture risk evaluation in patients with diabetes. * In diabetes,
fracture risk at T-score < −2 equivalent for non-diabetes at T-score < −2.5
(see text). ** Depending on country-specific guidelines for therapies. ***
For example, with TBS and/or BRA^ – yes. +Diabetes-specific CRFs are
listed in Table 3. 1In certain countries, humerus or pelvis fractures are also
sufficient to initiate therapy; otherwise, more than non-vertebral non-hip
fragility fracture could be required to initiate therapy; alternatively, a non-
vertebral non-hip fragility fracture should prompt further exams to eval-
uate fracture risk
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at more favorable FRAX and BMD values in diabetic than
in non-diabetic patients, as both BMD and FRAX may un-
derestimate the risk of fracture in this population.
Alternatively, FRAX estimates should be adjusted upwards
in diabetics (see below).
BMD intervention thresholds
If available, a BMD T-score < −2.5 at spine or hip in postmen-
opausal women and men over age 50 years confirms the diag-
nosis of osteoporosis and the need to consider pharmacothera-
py, whether or not diabetes is present (Table 3). However, T-
scoreBMDmeasuredbyDXAmayunderestimate fracture risk
inpatientswithdiabetes.Thus,aBMDintervention thresholdat
T-score − 2 at spine or hip could be considered appropriate
(Fig. 1). Regrettably, this suggested adjustment and absolute
cut-off although possibly appropriate in western populations
may not be applicable to populations from Asia and the
Middle East, where both age- and gender-adjusted BMD and
fracture rates are lower than that inwestern counterparts but has
not been shown specifically in the diabetes population.
Moreover, diabetic patients with prominent BMD loss up-
on two consecutive measurements (i.e., > = 5% after 2 years)
and when measurements are close to the intervention thresh-
old might be considered for treatment (Fig. 1).
FRAX®
Conventional clinical risk factors (CRFs) can be employed to
identify patients with diabetes at increased fracture risk (Table
3), although risk assessment tools like FRAX do not fully cap-
ture these increased risks and thus systematicallyunderestimate
the risk of osteoporosis-related fractures in patients with type 2
diabetes [45, 102].Hence, for agivenFRAXscore, fracture risk
was actually higher in type 2 diabetes patients compared to
patients without type 2 diabetes [45]. Diabetes has been shown
to be a significant predictor of subsequent major osteoporotic
fracture even after correcting for those CRFs included in risk
assessment tools like FRAX [102]. The TBS adjustment to
FRAXwill capture some of the excess fracture risk associated
with type 2 diabetes [50, 103].
Since type 2 diabetes confers an increased risk of fracture
that is independent of conventional CRFs, it has been pro-
posed that type 2 diabetes be considered for inclusion in future
iterations of FRAX [102]. It has been estimated that the frac-
ture risk in diabetes calculated with FRAX is equivalent to
adding 10 years of age or reducing the BMD T-score by 0.5
SD [45]. One option is to substitute rheumatoid arthritis (RA)
with type 2 diabetes in FRAX.We are of the opinion that such
a FRAX adjustment for type 2 diabetes can be clinically useful
despite limitations, and we recommend that FRAX be
employed to assess fracture risk in type 2 diabetes by
substituting RAwith type 2 diabetes [104] (Fig. 1).
General measures: lifestyle intervention
Lifestyle intervention is always recommended in patients with
diabetes and it is the basis of any clinical guidelines. However,
weight loss is associated with both muscle and bone loss that
may increase the risk of bone fragility and sarcopenia [105].
Sarcopenia and sarcopenic-obesity are risk factors for falls, and
frailty and should be prevented by an adequate protein intake
and weight-bearing exercise [106, 107]. Physical activity helps
to prevent bone loss during a weight loss program and is asso-
ciatedwith decreased sclerostin [108]with improvement in qual-
ity of life [109] even in the elderly. Other non-pharmacological
measures such as avoidance of smoking and limitation in alco-
hol intake (< 3 units per day) always remain important.
At diagnosis, serum 25-hydroxy-vitamin D levels have
been found to be lower in patients with type 1 diabetes than
in age-matched controls [110]. Lower levels of vitamin D are
associated with type 2 diabetes as well [111], mostly in the
obese and insulin-resistant states. Although the benefits of
vitamin D supplementation on bone have not been demon-
strated in diabetics, by analogy with the non-diabetic popula-
tion a daily vitamin D intake of 800 IU/day may be recom-
mended, although it may not be sufficient in type 2 diabetes
and progressive higher doses could be required to achieve
optimal serum levels (30 ng/ml). An adequate calcium intake
(preferably from diet) (1000 mg/day) is recommended as well.
Glycemic control
A strong association between complications of diabetes and
fracture risk has been documented [4, 7, 13]. The established
higher propensity for falls in the individual with diabetes [14,
112,113]probablyalsocontributes to the increasedfracture risk
observed in this population. Peripheral neuropathy, retinopathy
and any visual impairment, recent fall history, tendency to
Table 3 Risk factors for fractures in diabetes
Common risk factors
FRAX CRF*
Low BMD
Recurrent falls
Disease-specific risk factors
Diabetes duration > 5 years
Diabetes medication: insulin, TZDs, possibly SGLT2 inhibitors
HbA1c > 7%
Microvascular complications: peripheral and autonomic neuropathy,
retinopathy, nephropathy
CRF clinical risk factor, BMDbonemineral density, TZD thiazolidinedione,
SGL2 sodium-glucose cotransporter 2, Hb1Ac glycated hemoglobin A1c
*Age, sex, weight, height, previous fracture, family history of hip frac-
ture, current smoking, glucocorticoid, rheumatoid arthritis, alcohol, BMD
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hypoglycemia,hypotension,andautonomicneuropathyshould
be noted and where possible corrected (Table 3).
Tight glycemic control (HbA1c 6.5–6.9%) was associated
with the lowest risk of fracture in a large cohort of elderly
patients with diabetes [114]. However, both hypoglycemia
and hyperglycemia are associated with increased risk of frac-
tures and falls [11], though probably via different mecha-
nisms. Therefore, mostly in the elderly, a less stringent glyce-
mic control in order to avoid risk of hypoglycemic events (and
consequently of falls) has been proposed [115] and recently
recommended by EASD/ADA guidelines [116].
Anti-diabetic treatments such as thiazolidinediones should
be avoided in diabetics with bone fragility [27]. Canagliflozin,
but not necessarily all SGLT2 inhibitors, should also probably
be avoided in these patients [32]. Medications with a neutral
or favorable effect on bone metabolism, such as metformin
and incretin-based treatments, should be the preferred treat-
ment [38, 40].
Osteoporosis treatment
At this time and in the absence of strong evidence against,
bisphosphonates remain the first choice for osteoporosis treat-
ment in diabetic patients.Although there are no specific data on
the efficacy of denosumab in diabetic patients, this may be a
preferredoption indiabetic patientswho are older and/or havea
declining renal function.However, the use andpotential benefit
of anti-resorptive drugs in patients with type 2 diabetes charac-
terized by near normal BMD and/or normal or low bone turn-
overmarkers,whosebone fragilitymaymostly result frompoor
bone material properties, remains unproven and of potential
concern. In this context, teriparatide, and in the future
abaloparatide or romosozumab, present a potential interest.
Conclusion
Patients with diabetes are at increased risk of fragility fractures.
While the pathophysiology of bone fragility in these patients is
not entirely clear, it is likely multifactorial. Longitudinal stud-
ies have established that FRAX and BMDT-score predict frac-
ture risk in those with type 2 diabetes but both require adjust-
ment for diabetes to avoid underestimation of risk. The optimal
approach to management of patients with diabetes has not yet
been established based on prospective clinical studies. Hence,
our currently proposed algorithm should be considered as a
consensus among some experts which may change over time
as more evidence will be gathered. Data would suggest that if a
patient has indication for therapy based on criteria developed
for non-diabetes patients, these patients should be treated with
osteoporosis drugs. In absence of established osteoporosis
though, these medications may be used with caution though,
as the effects of these drugs in situations where bone fragility is
mainly due to alterations in bone quality remain to be thor-
oughly evaluated. Future studies should continue to evaluate
the structural determinants (microstructure, material properties,
…) of bone fragility and refine the fracture prediction algo-
rithms by including disease-specific determinants of fracture
(Table 3). New trials will have to prospectively investigate the
efficacy and safety of osteoporosis treatment in diabetics with
and without low aBMD.
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